Drug Profile
GSK 3191607
Alternative Names: [14C] - GSK 3191607; GSK3191607Latest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antimalarials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Falciparum malaria
Most Recent Events
- 28 May 2019 No recent reports of development identified for phase-I development in Falciparum-malaria(In volunteers) in United Kingdom (IV, Infusion)
- 01 May 2016 GlaxoSmithKline completes a phase I trial in Falciparum malaria (In volunteers) in United Kingdom (IV) (NCT02737007)
- 07 Apr 2016 GlaxoSmithKline plan a phase I trial in Healthy male volunteers in United Kingdom (IV) (NCT02737007)